Table 5:
End-organ function | PVRrest r (p) | mPAP/CO slope r (p) | Meng test p | PVRrest β (95%CI) | mPAP/CO slope β (95%CI) | p |
---|---|---|---|---|---|---|
Endothelial function | ||||||
EndoPAT-derived RHI | −0.31 (0.04) | −0.63 (<0.001) | 0.02 | −0.06 (−0.12 – −0.01) | −0.11 (−0.18 – −0.0) | <0.001 |
End-organ function | ||||||
MRE liver stiffness | 0.29 (0.04) | 0.47 (0.008) | 0.07 | 0.08 (0.02 – 1.98) | 0.21 (2.84 – 5.57) | <0.001 |
GFR | −0.24 (0.07) | −0.52 (<0.001) | 0.03 | −0.03 (−0.07 – 0.01) | −0.09 (−0.13 – −0.04) | 0.008 |
NT-proBNP | 0.17 (0.2) | 0.56 (<0.001) | 0.02 | 0.05 (−0.13 – 0.19) | 0.26 (0.14 – 0.39) | <0.001 |
Est plasma volume | 0.08 (0.5) | 0.24 (0.1) | 0.4 | 0.01 (−0.16 – 0.14) | 0.06 (−0.09 – 0.21) | 0.2 |
Peak VO2 | −0.26 (0.09) | −0.63 (<0.001) | 0.02 | −0.06 (−0.11 – 0.02) | −0.19 (−0.30 – −0.04) | 0.01 |
MLHFQ | 0.22 (0.1) | 0.28 (0.08) | 0.4 | 0.01 (−0.18 – 0.20) | 0.07 (−0.03 – 0.15) | 0.5 |
PVR: pulmonary vascular resistance; mPAP/CO slope: slope of mean pulmonary artery pressure versus cardiac output; RHI: reactive hyperemia index; MRE: magnetic resonance elastography; GFR: glomerular filtration rate; NT proBNP: N-terminal pro hormone brain natriuretic peptide; VO2: oxygen consumption; MLHFQ: Minnesota living with heart failure questionnaire; CI: confidence interval